Skip to main content
FinSpry Logo
FinSpry
HALO logo
HALO
(NASDAQ)
Halozyme Therapeutics, Inc.
$64.49-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Halozyme Therapeutics (HALO) Stock Price & Financial Analysis

Halozyme Therapeutics Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$63.61 - $65.65
52-Week High$82.22
52-Week Low$47.50
Open$64.22
Volume1.32M
Average Volume (3M)1.32M
Market Cap7.99B
Shares Outstanding123.90M
P/E Ratio (TTM)25.57
Forward P/E34.03
Price to Sales (P/S)5.80
Price to Book (P/B)166.00
EV/EBITDA8.63
Revenue (TTM)1.40B
Net Income (TTM)316.89M
Free Cash Flow (TTM)644.59M
EPS (TTM)$2.69
Profit Margin22.69%
Operating Margin58.45%
Return on Equity (ROE)649.18%
Debt to Equity0.00
50-Day MA$70.01
200-Day MA$67.25
52-Week Change5.71%
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%

Frequently Asked Questions About Halozyme Therapeutics

What is the current stock price for HALO?

As of the latest trading session, HALO stock trades at $64.49. The 52-week range is $47.50–$82.22, with a day range of $63.61–$65.65.

What is the P/E ratio for HALO?

Halozyme Therapeutics's trailing P/E ratio is 25.6, meaning investors pay $25.6 for every $1 of annual earnings. The forward P/E is 34.0, reflecting analyst expectations for future earnings. Halozyme Therapeutics operates in the Healthcare sector.

Does HALO pay dividends?

Halozyme Therapeutics does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for HALO?

Based on 4 analysts, the consensus for HALO is Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of HALO?

Halozyme Therapeutics's market capitalization is $7.99B, classifying it as a mid-cap company. Halozyme Therapeutics operates in the Healthcare sector within the Biotechnology industry.